Prostate Cancer

... YM BioSciences' partner, Oncoscience AG, cleared for Phase III trial in Germany with nimotuzumab YM BioSciences' partner, Oncoscience AG, cleared for Phase III trial in Germany with nimotuzumab - Phase II results presented at the 27th Annual German Cancer Conference - MISSISSAUGA, ON, March 28 /PRNewswire-FirstCall/ - YM BioSciences Inc.

(AMEX:YMI, TSX:YM, AIM:YMBA), the cancer product development company, today announced that its partner, Oncoscience AG, has been cleared by the German regulatory authority for biological products, the Paul Ehrlich Institute, to initiate a Phase III trial of nimotuzumab in combination with radiation in children with inoperable pontine (brain stem) glioma.

The clinical trial was also reviewed with the EMEA and is designed as a prospectively registrable study on the basis of a single arm trial because of the absence of treatment options for children suffering from pontine glioma.

It is anticipated that marketing authorization subsequent to a successful trial would be sought under the EMEA centralized procedure.

The trial is a single arm study in which 40 children with inoperable pontine glioma will be treated with radiation concomitant with nimotuzumab.

The primary clinical endpoints in the trial will be Progression-Free Survival at 3, 6, 12 and 24 months with Median Survival as secondary endpoint.

Clinical sites will be located in Germany, Italy, Belarus and Russia and it is anticipated that recruitm...

Read more...